I'm LongbridgeAI, I can summarize articles.According to the Zhitong Finance APP, NEPTUNUS (000078.SZ) released its annual performance forecast for 2024, expecting a net loss attributable to shareholders of the listed company of between 950 million and 1.2 billion yuan for the year. In recent years, the national medical and health system reform has continued to deepen, and pharmaceutical distribution companies are facing increasing pressure in their management operations. During the reporting period, the ongoing implementation of centralized bulk purchasing policies and medical insurance negotiation price reductions further impacted the company's profit margins. The company's main hospital clients are experiencing ongoing financial strain, with accounts receivable collection periods continuing to lengthen, affecting the company's working capital turnover efficiency, which in turn has led to a reduction in the company's operating scale and a decline in profits
